SCHEMBL2651405

SCHEMBL2651405

Nc1nncc(C(F)(F)F)n1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
KDM4E B2RXH2 6/20 0.39
HSD17B10 Q99714 2/20 0.39
ADORA2A P29274 5/20 0.37
ADORA1 P30542 5/20 0.37
ALDH1A1 P00352 3/20 0.37
GRM4 Q14833 1/20 0.35
CA2 P00918 1/20 0.34
CHKA P35790 1/20 0.34
PTGS2 P35354 1/20 0.33
TRPV4 Q9HBA0 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30754263 1.00 HSP90AA1 (0.45) HSP90AA1HSP90AB1KDM4EHSD17B10ADORA2A
SCHEMBL2657204 0.83 HSP90AA1 (0.38) HSP90AA1HSP90AB1KDM4EHSD17B10ADORA2A
SCHEMBL2652226 0.83 HSP90AA1 (0.38) HSP90AA1HSP90AB1KDM4EHSD17B10ADORA2A
SCHEMBL30775679 0.77 HSD17B10 (0.42) HSP90AA1HSP90AB1KDM4EHSD17B10ADORA2A
SCHEMBL2651105 0.74 ADORA2A (0.35) HSP90AA1HSP90AB1HSD17B10ADORA2AADORA1
SCHEMBL12707369 0.71 HSD17B10 (0.34) HSD17B10ADORA2AADORA1
SCHEMBL2044604 0.70
SCHEMBL10900625 0.70 HSP90AA1 (0.71) HSP90AA1HSP90AB1KDM4EHSD17B10ADORA2A
SCHEMBL12707361 0.69 ADORA2A (0.32) ADORA2AADORA1
SCHEMBL25422152 0.68 ALDH1A1 (0.46) KDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451161-B1 IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME (GB) 2007-04-18 EP disclosed
US-7176203-B2 Imidazo-triazine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. 2007-02-13 US disclosed
US-20060058303-A1 Imidazo-triazine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2006-03-16 US disclosed
US-7005431-B2 Imidazo-triazine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. 2006-02-28 US disclosed
US-20060040940-A1 Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands BETTATI MICHELA 2006-02-23 US disclosed
EP-1343788-B1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-11-23 EP disclosed
EP-1409488-B1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-11-16 EP disclosed
US-6936608-B2 Imidazo-triazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LTD. 2005-08-30 US disclosed
US-20050165023-A1 Imidazo-triazine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2005-07-28 US disclosed
EP-1504007-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2005-02-09 EP disclosed
US-20040023964-A1 Imidazo-triazine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2004-02-05 US disclosed
US-20030216395-A1 Imidazo-triazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2003-11-20 US disclosed
WO-2003093273-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2003-11-13 WO disclosed
WO-2003093272-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2003-11-13 WO disclosed
EP-1343788-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2003-09-17 EP disclosed
US-6617326-B2 For therapy and prophylaxis of adverse conditions of the central nervous system, including anxiety and convulsions MERCK SHARP & DOHME LTD. 2003-09-09 US disclosed
WO-2003048132-A1 IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2003-06-12 WO disclosed
US-20030055060-A1 Imidazo-triazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LTD. (GB) 2003-03-20 US disclosed
WO-2003008418-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2003-01-30 WO disclosed
WO-2002038568-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040940-A1 Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands CHRNA3, GABRA3, GABRB3 HSP90AA1 3421/4885HSP90AB1 3148/4885KDM4E 3211/4885
US-20030216395-A1 Imidazo-triazine derivatives as ligands for GABA receptors GABRA2, GABRA3, GABRA1 HSP90AA1 1369/4885HSP90AB1 1704/4885KDM4E 2603/4885
US-20040023964-A1 Imidazo-triazine derivatives as ligands for gaba receptors GABRA2, GABRA5, GABRA1 HSP90AA1 1193/4885HSP90AB1 1263/4885KDM4E 3624/4885
US-20050165023-A1 Imidazo-triazine derivatives as ligands for gaba receptors GABRA5, GABRA3, GABRA2 HSP90AA1 1525/4885HSP90AB1 1557/4885KDM4E 3366/4885
US-20060058303-A1 Imidazo-triazine derivatives as ligands for gaba receptors GABRA5, GABRA3, GABRA2 HSP90AA1 1857/4885HSP90AB1 1974/4885KDM4E 3505/4885
US-20030055060-A1 Imidazo-triazine derivatives as ligands for GABA receptors GABRA2, GABRA1, GABRA3 HSP90AA1 1342/4885HSP90AB1 1579/4885KDM4E 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.